Lee Alvin, Hawkes David, Sweeney Daniel, Wyatt Kerryann, Nightingale Claire, Chalmers Corey, Saville Marion
Australian Centre for the Prevention of Cervical Cancer, Melbourne, Australia.
Department of Biochemistry and Pharmacology, The University of Melbourne, Melbourne, Australia.
BMC Med. 2025 Jul 1;23(1):389. doi: 10.1186/s12916-025-04219-3.
Australia is working towards eliminating cervical cancer as a public health issue by 2035, by achieving an incidence rate of less than 4 cases per 100,000 people. Increasing cervical screening participation, particularly in under-screened groups, is critical to achieving this goal equitably. On 1 December 2017, the National Cervical Screening Program (NCSP) transitioned from two-yearly Papanicolaou smear-based screening to five-yearly primary human papillomavirus (HPV) based cervical screening tests (CST) for all women and people with a cervix aged 25-74 years. Since July 2022, all eligible participants can choose to undertake self-collected CST, a collection method to help overcome barriers to screening. We aimed to investigate self-collection uptake in Victoria, including HPV positivity rates and time to colposcopy, after universal availability.
We investigated self-collection uptake by age group, regionality, and screening status as a proportion of all CST from 1 December 2017 until 30 June 2024. We also compared rates of HPV detection, invalid results, and time to colposcopy with practitioner-collected samples during the same period. The analysis presented was conducted using the March 2025 Victorian raw data extract sourced from the National Cancer Screening Register and publicly available screening coverage rates in Victoria. R was used to prepare our descriptive analysis.
Twenty-nine percent of the 598,055 CST from 1 July 2022 to 30 June 2024 were self-collected compared with 0.41% of 1,279,416 tests prior to universal availability. The findings indicate a notable increase in self-collection uptake in older age groups, regional areas, and under- and never-screened women. While uptake of self-collection increased, there was a reduction in overall screening coverage in 2023. The median time to colposcopy assessment was similar for women who used self-collection and practitioner-collected screening. HPV positivity and invalid rates were low for both collection methods, although there were slightly higher overall positivity and invalid rates in self-collected tests.
Self-collection was used by a wide range of NCSP participants when universally available, despite a reduction in overall screening coverage. Our findings offer insights for programs seeking to widen population level availability of self-collection for cervical screening.
澳大利亚正致力于到2035年消除宫颈癌这一公共卫生问题,目标是将发病率降至每10万人中少于4例。提高宫颈癌筛查参与率,尤其是在筛查不足的人群中,对于公平实现这一目标至关重要。2017年12月1日,国家宫颈癌筛查计划(NCSP)从基于两年一次巴氏涂片的筛查转变为对所有25至74岁的女性和有子宫颈的人群进行基于人乳头瘤病毒(HPV)的五年一次宫颈癌筛查测试(CST)。自2022年7月起,所有符合条件的参与者都可以选择自行采集CST,这是一种有助于克服筛查障碍的采集方法。我们旨在调查在普遍提供自行采集方法后,维多利亚州的自行采集使用率,包括HPV阳性率和转诊阴道镜检查的时间。
我们调查了2017年12月1日至2024年6月30日期间,按年龄组、地区和筛查状态划分的自行采集使用率,以其占所有CST的比例来衡量。我们还比较了同一时期自行采集样本与医护人员采集样本的HPV检测率、无效结果率以及转诊阴道镜检查的时间。所呈现的分析是使用2025年3月从国家癌症筛查登记处获取的维多利亚州原始数据提取物以及维多利亚州公开的筛查覆盖率进行的。我们使用R软件进行描述性分析。
在2022年7月1日至2024年6月30日期间的598,055次CST中,29%是自行采集的,而在普遍提供自行采集方法之前的1,279,416次检测中,这一比例为0.41%。研究结果表明,老年组、地区以及未筛查和从未筛查过的女性中,自行采集的使用率显著增加。虽然自行采集的使用率有所上升,但2023年的总体筛查覆盖率有所下降。自行采集筛查和医护人员采集筛查的女性转诊阴道镜检查评估的中位时间相似。两种采集方法的HPV阳性率和无效率都较低,不过自行采集检测的总体阳性率和无效率略高。
尽管总体筛查覆盖率有所下降,但在普遍提供自行采集方法后,NCSP的众多参与者都采用了这种方式。我们的研究结果为旨在扩大宫颈癌筛查自行采集方法在人群层面可及性的项目提供了见解。